Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
- Solid tumors
NEWS & FEATURES
Pedmark Approved for Pediatric Cisplatin-Associated Ototoxicity
Tucatinib + Trastuzumab Granted Priority Review for HER2-Positive Metastatic Colorectal Cancer
Sugar-Sweetened Drink Intake Linked to Mortality From Some Cancers
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
Oral CDK7 Inhibitor Granted Orphan Drug Status for Pancreatic Cancer
More Adolescents and Young Adults Enrolled in Trials After Launch of NCTN
Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
Rolvedon Approved for Chemotherapy-Induced Neutropenia
FDA: Cases of Breast Implant-Related SCC, Various Lymphomas Reported
August 2022 Recap: Drug Pipeline Update
August 2022: Notable Drug Approvals
Stimufend, a Biosimilar to Neulasta, Gets FDA Approval
No Increased Cancer Risk Found for Children Born After Use of ART
Imfinzi Plus Chemotherapy Approved for Advanced Biliary Tract Cancer
Pemazyre Approved for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
ACS Issues Nutrition, Exercise Guidelines for Cancer Survivors
Optimal Duration of Neoadjuvant Gemcitabine + Cisplatin for MIBC Probed
